Elevated Expression of the Testis-specific Gene WBP2NL in Breast Cancer

Seyedmehdi Nourashrafeddin1,2, Mehdi Dianatpour3,4, Mahmoud Aarabi5, Maryam Beigom Mobasher6,7, Golnesa Kazemi-oula6 and Mohammad Hossein Modarressi6

1School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran, 2Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, 3Department of Medical Genetics, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, 4Transgenic Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, 5Department of Human Genetics, School of Medicine, McGill University, Montreal, Canada, 6Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 7Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT: Breast cancer is one of the most common causes of cancer death in women; therefore, the study of molecular aspects of breast cancer for finding new biomarkers is important. Recent studies have shown that WW-domain-binding protein 2 (WBP2) is important for the oncogenic property of breast cancer. WWP2 N-terminal-like (WBP2NL) is a testis-specific signaling protein that induces meiotic resumption and oocyte activation events. Our previous study revealed that WBP2NL gene expression is elevated in actively dividing cells and it might be associated with cellular proliferation and tumorigenic process. However, the clinical relevance and importance of WBP2NL gene in cancer has not been understood yet. Therefore, we were interested in analyzing the expression of WBP2NL gene in human breast cancer tissues and breast cancer cell lines, for the first time. We used reverse transcription-polymerase chain reaction (RT-PCR) and semi-nested RT-PCR to evaluate the expression of WBP2NL in malignant breast cancer and adjacent noncancerous tissue (ANCT) samples, as well as MCF-7 and MDA-MB-231 cell lines. The WBP2NL gene was expressed in 45 out of 50 (90%) breast cancer tissues and overexpressed in the MDA-MB-231 cell line. We suggest that WBP2NL may play roles in breast cancer activation maybe through binding to a group 1 WW domain protein. The elevated expression of WBP2NL gene in breast cancer and MDA-MB-231 cell line leads us to suggest that WBP2NL might be considered as a novel prognostic factor for early diagnosis of breast cancer.

KEYWORDS: breast cancer, WBP2NL, gene expression, cancer/testis genes

Introduction

Breast cancer is the most frequent cause of cancer death in women worldwide. Approximately, 1 out of 10 women develops breast cancer during her lifetime.2 Genetic tests that evaluate the biology of cancer are usually used to understand more about breast cancer, particularly to help predict the cancer recurrence risk, and thereby to help choose appropriate treatment. Therefore, study on the molecular aspects of breast cancer to find the genes associated with breast cancer risk and new biomarkers for early diagnosis of breast cancer is very important.

Sertoli cells in the testis make a blood–testis barrier that provides an immune-privileged site for germ cell's antigens. Cancer/testis (CT) genes are a family of genes that are normally expressed during spermatogenesis, usually in spermatocytes, and also in various human cancers, but absent in normal somatic cells.2,3 Most CT genes induce cell proliferation and differentiation in normal testis, and have roles in meiosis.3 The aberrant expression of CT genes in cancerous cells might cause abnormality in chromosome segregation and cell divisions.3 Because of the blood–testis barrier and the immune-privileged status of testicular tissue, and also because of the probable roles of CT genes in oncogenesis, these immunogenic proteins are being strongly considered as potential targets for cancer vaccines and immunotherapy.4,5

Recent studies have demonstrated that WW-binding protein 2 (WBP2) activates the transcription of both estrogen and progesterone receptors (ERα/PR), and thereby is involved in the regulation of ERα/PR target genes and breast cancer.5–8 It has been revealed that WW domain-mediated interaction with WBP2 is important for the oncogenic properties of the PDZ-binding motif (TAZ) in breast cancer.5–11

WWP2 N-terminal like (WBP2NL), also known as post-acrosomal sheath WW domain-binding protein (PAWP), is a testis-specific protein and has no expression in other tissues. WBP2NL is a 32-kDa signaling molecule localized in the post-acrosomal sheath (PAS) of spermatozoa.9,10 In humans, the WBP2NL gene is located on chromosome 22q13.2 and consists of six exons extending over 29/69 kb.
The N-terminal part of WBP2NL has homology with WW domain binding protein-2, whereas the C-terminal part contains a PPXY motif that allows it to interact with group I WW domain proteins such as TAZ and the yes-associated protein (YAP). The WBP2NL protein enters the oocyte during fertilization, and induces meiotic resumption and oocyte activation events.14–16

A previous study by Aarabi et al has shown that WBP2NL contributes to sperm-induced calcium release and thereby initiates oocyte activation events.17 Our previous study revealed that WBP2NL is expressed in embryonic stem cells and actively dividing cancerous cell lines, and we suggested that it might be associated with cellular proliferation and tumorigenic processes.18 However, the mechanisms of WBP2NL in cell proliferation and its clinical relevance have not been understood yet. In the present study, we examined the expression of WBP2NL in normal and breast cancer tissues as well as in breast cancer cell lines in order to get more insights into its potential role in cellular proliferation and carcinogenesis, for the first time.

Materials and Methods

Patient and normal tissue samples. The study included 50 breast cancer tissues and 30 adjacent noncancerous tissue (ANCCT) samples obtained from Imam Khomeini Hospital affiliated to Tehran University of Medical Sciences (Table 1). All patients had been diagnosed on the basis of clinical and laboratory findings (Table 2). Normal testis tissue, as positive control for WBP2NL gene expression, was obtained from a prostate cancer patient after orchietomy. The study complied with the good clinical practice according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all subjects participating in the study.

Cell culture. The human breast cancer cell lines MCF-7 and MDA-MB-231 were obtained from Pasteur Institute of Iran and cultured according to the manufacturer's instruction.

Table 1. Major pathological features and characteristics of patients.

| SUBJECT CHARACTERISTICS | NO. OF SUBJECTS (n = 50) |
|-------------------------|--------------------------|
| Age (years)             | 35–65 (mean: 50)         |
| Histology               |                          |
| Ductal                  | 46 (92%)                 |
| Others                  | 4 (8%)                   |
| Grade                   |                          |
| 1                       | 10 (20%)                 |
| 2–3                     | 40 (80%)                 |
| HER2/neu                |                          |
| Negative                | 37 (74%)                 |
| Positive                | 13 (26%)                 |
| ER/PR                   |                          |
| Negative                | 12 (25%)                 |
| Positive                | 38 (75%)                 |

Reverse1: 5′-TTAAAGATGGACCTGAGAGAGG-3′
Reverse2: 5′-GGCTCCATAGACAATAACTGAAC-3′

with slight modification. Cells were cultured in RPMI medium with 10% fetal bovine serum (FBS) at 37°C and 5% CO2. After 2 days, the cells were harvested and about 2 x 106 cells were separated for RNA extraction, cDNA synthesis, and reverse-transcription polymerase chain reaction (RT-PCR) experiments.

RNA extraction and cDNA synthesis. Total RNA was extracted from tumor and normal samples and also breast cancer cell lines by TriPure isolating reagent (Roche) according to the manufacturer’s instructions with slight modifications. RNA was dissolved in DEPS–treated water and its concentration was determined by a spectrophotometer (NanoDrop 2000). About 2 µg of total RNA from various samples were subjected for cDNA synthesis using the M-MLV reverse transcription kit (Invitrogen) and random primer (Pharmacia, Sweden).

RT-PCR and semi-nested PCR. A couple of specific primers of the housekeeping gene hypoxanthine–guanine phosphoribosyltransferase-1 (HPRT1) were used to ascertain the cDNA quality. PCR amplification of HPRT was performed in five minutes at 94°C as start denaturation, 30 cycles of denaturation at 94°C for 40 seconds, annealing at 59°C for 30 seconds, extension at 72°C for 30 seconds, and a 7-minute final extension at 72°C. A pair of specific primers was designed to amplify 567 base pair fragments of human WBP2NL. The total reaction volumes were 25 µL containing 1 µL cDNA, two specific primers, PCR set, and smart Taq polymerase (Invitrogen). The PCR amplification of WBP2NL was performed with 35 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, extension at 72°C for 30 seconds, and a 7-minute final extension at 72°C following an initial denaturation of 4 minutes at 94°C. The primers were positioned in different exons of each gene to avoid false positive results because of probable genomic DNA contamination. If no expression of WBP2NL was detected in RT-PCR runs on agarose gel, semi-nested PCR was performed using 2 µL of the first PCR reactions. Negative control reaction of the first PCR was used for the semi-nested PCR to identify false positive results caused by genomic DNA contamination. In order to carry out semi-nested PCR, an internal forward primer was used to amplify 168 base pair fragments of WBP2NL. The semi-nested amplification of WBP2NL was performed with 35 cycles of denaturation at 94°C for 30 seconds, annealing at 57°C for 20 seconds, extension at 72°C for 30 cycles, and a 7-minute final extension at 72°C, following an initial denaturation of 4 minutes at 94°C. PCR products were subjected to electrophoresis in 1.5% agarose gel and then visualized under ultraviolet light after DNA staining with ethidium bromide. Amplification reaction carried out using following designed primers:

HPRT Forward: 5′-ACCAGTCAACAGGGGGACATAA-3′
Reverse: 5′-CTTCGTGGGGTCCTTTTCACC-3′

WBP2NL Forward: 5′-GCCATTGAATTTGGCCCACTTG-3′
Reverse1: 5′-TTAAGATGGACCTGAGAGGG-3′
Reverse2: 5′-GGCTCCATAGACAATAACTGAAC-3′
Table 2. Classification of pathological features and WBP2NL expression from breast cancer patients.

| NO. | PATIENT CODE | AGE | CANCER HISTOLOGY | CANCER GRADE | HER2/neu EXPRESSION | ER EXPRESSION | PR EXPRESSION | WBP2NL OVER EXPRESSION (FIRST PCR) | NESTED PCR |
|-----|--------------|-----|------------------|--------------|---------------------|---------------|--------------|------------------------------------|------------|
| 1   | T201         | 47  | ISDC             | II           | –                   | +++           | +            | –                                  | +          |
| 2   | T202         | 57  | IDC              | II           | +++                 | –             | –            | +                                  | +          |
| 3   | T203         | 62  | IDC              | III          | ++                  | +             | +            | ++                                 | +          |
| 4   | T204         | 44  | ISDC             | I            | –                   | +             | +            | –                                  | +          |
| 5   | T205         | 57  | IDC              | II           | ++                  | –             | –            | –                                  | +          |
| 6   | T206         | 48  | ISDC             | II           | –                   | +             | –            | –                                  | –          |
| 7   | T207         | 35  | IDC              | III          | ++                  | ++            | +            | +                                  | +          |
| 8   | T208         | 39  | IDC              | II           | –                   | –             | +            | –                                  | +          |
| 9   | T209         | 52  | ISDC             | II           | –                   | +             | ++           | –                                  | +          |
| 10  | T210         | 41  | IDC              | III          | +++                 | –             | –            | +++                               | +          |
| 11  | T211         | 46  | ISDC             | I            | –                   | +             | ++           | –                                  | –          |
| 12  | T212         | 63  | ISDC             | II           | –                   | +             | –            | +                                  | +          |
| 13  | T213         | 51  | IDC              | II           | –                   | –             | –            | ++                                 | +          |
| 14  | T214         | 49  | ISDC             | I            | –                   | +++           | –            | –                                  | +          |
| 15  | T215         | 55  | ISDC             | II           | –                   | +             | ++           | –                                  | +          |
| 16  | T216         | 44  | ISDC             | II           | –                   | –             | –            | –                                  | +          |
| 17  | T217         | 61  | ISDC             | I            | –                   | ++            | –            | +                                  | +          |
| 18  | T218         | 42  | IDC              | III          | +++                 | –             | –            | +++                               | +          |
| 19  | T219         | 47  | ISDC             | II           | –                   | +             | +++          | –                                  | +          |
| 20  | T220         | 35  | IMC              | II           | +                   | +             | +            | –                                  | +          |
| 21  | T221         | 58  | IDC              | II           | +++                 | –             | –            | –                                  | –          |
| 22  | T222         | 53  | IDC              | II           | ++                  | –             | –            | ++                                 | +          |
| 23  | T223         | 50  | ISDC             | II           | –                   | ++            | +            | –                                  | +          |
| 24  | T224         | 48  | IMC              | II           | –                   | +             | ++           | –                                  | +          |
| 25  | T225         | 37  | ISDC             | II           | –                   | –             | –            | –                                  | +          |
| 26  | T226         | 47  | IDC              | II           | ++                  | +             | –            | +++                               | +          |
| 27  | T227         | 60  | ISDC             | II           | –                   | ++            | +            | –                                  | +          |
| 28  | T228         | 45  | ISDC             | I            | –                   | +             | ++           | –                                  | +          |
| 29  | T229         | 63  | IDC              | II           | –                   | +             | –            | –                                  | +          |
| 30  | T230         | 55  | IDC              | II           | –                   | ++            | +            | +++                                | +          |
| 31  | T231         | 38  | ISDC             | I            | –                   | ++            | –            | –                                  | +          |
| 32  | T232         | 65  | ISDC             | II           | –                   | ++            | –            | –                                  | +          |
| 33  | T233         | 44  | IDC              | II           | –                   | –             | –            | ++                                 | +          |
| 34  | T234         | 51  | ISLC             | II           | –                   | +             | ++           | +                                  | +          |
| 35  | T235         | 58  | IDC              | III          | +++                 | –             | –            | +                                  | +          |
| 36  | T236         | 43  | IDC              | II           | –                   | –             | ++           | –                                  | +          |
| 37  | T237         | 41  | ISDC             | I            | –                   | +             | +++          | –                                  | –          |
| 38  | T238         | 57  | ISDC             | I            | –                   | ++            | +            | –                                  | +          |
| 39  | T239         | 50  | IDC              | II           | –                   | +             | –            | +++                                | +          |
| 40  | T240         | 49  | IMC              | II           | –                   | +             | –            | –                                  | +          |
| 41  | T241         | 52  | ISDC             | II           | –                   | +             | ++           | –                                  | +          |
| 42  | T242         | 37  | ISDC             | I            | –                   | ++            | +            | –                                  | +          |
| 43  | T243         | 48  | IDC              | II           | –                   | –             | –            | –                                  | +          |
| 44  | T244         | 62  | IDC              | III          | +++                 | –             | +            | ++                                 | +          |

(continued)
Statistical analysis. Statistical analysis was carried out using the SPSS software (SPSS Inc.), and significance was defined as \( P < 0.05 \).

Results

Complementary DNA amplification obtained from breast tumor samples was carried out with specific primers for \( WBP2NL \) gene using RT-PCR. We carried out semi-nested RT-PCR method in order to analyze the semiquantitative expression level of \( WBP2NL \).

We detected \( WBP2NL \) expression in 45 out of 50 (90%) breast cancer samples (Fig. 1). Fifteen (30%) cases expressed \( WBP2NL \) in the first round of RT-PCR, representing a high level of gene expression (Fig. 1A), and 30 (60%) cases expressed \( WBP2NL \) in the second amplification by semi-nested RT-PCR, representing a low level of \( WBP2NL \) expression in the samples (Fig. 1B). Negative results from semi-nested RT-PCR showed a nondetectable \( WBP2NL \) transcript in the breast cancer samples (Fig. 1B). No expression of \( WBP2NL \) was seen in ANCT samples (Fig. 2). The different levels of \( WBP2NL \) gene expression in normal and breast cancer tissues are summarized in Tables 2 and 3.

![RT-PCR results from breast cancer samples, testis tissue, and breast cancer cell lines. (A) RT-PCR was performed to analyze of \( WBP2NL \) gene expression in breast cancer samples, testis tissue, and cell lines. Lane 1 and 2 are cDNA from MCF-7 and MDA-MB-231 cell line, respectively. Lane 3 is cDNA from an adult human testis as a positive control. Lanes 4–12 are cDNAs from breast cancer samples, Lane 13 is the negative control (water), and Lane 14 is 100 bp DNA marker. (B) Nested PCR was performed to analyze low expression of \( WBP2NL \) gene in breast cancer and cell lines. (C) All samples were controlled for presence of cDNA using the housekeeping gene HPRT.](image)

![RT-PCR results from ACNT samples. (A) Presence of cDNA was checked in all samples using the housekeeping gene HPRT. (B) Lanes 2–7 are results of RT-PCR from some ACNT samples which showed no \( WBP2NL \) gene expression. (C) Nested PCR was carried out, which showed no expression of \( WBP2NL \) gene in ACNT samples (Lanes 2–7). Lane 1 was a negative control (water) and Lane 8 was RT-PCR from an adult human testis as a positive control. Lane 9 is a 100-bp DNA marker.](image)

Table 2. (Continued)

| NO. | PATIENT CODE | AGE | CANCER HISTOLOGY | CANCER GRADE | HER2/neu EXPRESSION | ER EXPRESSION | PR EXPRESSION | \( WBP2NL \) OVER EXPRESSION (FIRST PCR) | NESTED PCR |
|-----|--------------|-----|------------------|-------------|---------------------|---------------|-------------|--------------------------------|-----------|
| 45  | T245         | 44  | IDC              | II          | +                   | +             | +           | -                                | +         |
| 46  | T246         | 57  | ISDC             | I           | -                   | +             | ++          | -                                | -         |
| 47  | T247         | 48  | ISDC             | II          | -                   | -             | ++          | -                                | -         |
| 48  | T248         | 35  | ISLC             | II          | -                   | +             | -           | -                                | +         |
| 49  | T249         | 39  | IMC              | II          | -                   | ++            | +           | -                                | +         |
| 50  | T250         | 56  | ISDC             | II          | -                   | +             | ++          | -                                | +         |

Notes: +++ means similar band in Figure 1 Lane A5; ++ means similar band in Figure 1 Lane A8; + means similar band in Figure 1 Lane A12.

Abbreviations: IDC, infiltrating ductal carcinoma; IMC, infiltrating mucinous carcinoma; ISDC, in situ ductal carcinoma; ISLC, in situ lobular carcinoma.

Analysis of the \( WBP2NL \) gene expression levels was examined in women of two different age groups with breast cancer: young (35–50 years) and elderly (51–65 years), but no significant association was detected between age and the gene expression.

For more information, we evaluated the correlation between the histological feature and grade status of tumor samples and \( WBP2NL \) expression. A significant difference was detected in \( WBP2NL \) gene expression levels and the type of infiltrating ductal carcinoma (\( P < 0.01 \)). We also analyzed the correlation between \( WBP2NL \) gene expression levels and additional factors including ER/PR and HER2/neu expression of tumor samples. A significant difference was detected in \( WBP2NL \) gene expression levels and HER2/neu expression (\( P < 0.05 \)).

Fifteen peripheral blood samples from breast cancer patients were examined for the expression of \( WBP2NL \), but the transcript was not found in the peripheral blood samples from patients using RT-PCR (data not shown).

We also evaluated \( WBP2NL \) expression in the breast cancer cell lines MCF-7 and MDA-MB-231 (Table 3). The latter cell line showed expression of \( WBP2NL \) in the first round of RT-PCR, whereas the expression of \( WBP2NL \) was negative in RT-PCR and semi-nested RT-PCR (Fig. 1).
Table 3. **WBP2NL gene expression in all samples after two rounds amplification (first PCR and semi-nested PCR).**

| **WBP2NL GENE EXPRESSION** | **SAMPLE TYPE** | **ANCT** | **BC** | **MDA-MB-231** | **MCF-7** |
|----------------------------|-----------------|----------|--------|----------------|----------|
| Positive in the first PCR (high expression) |                  | 0 (0%)   | 15 (30%) | 2 (100%)       | 0 (0%)   |
| Positive in the semi-nested PCR out of negatives in the first PCR (low expression) |                  | 0 (0%)   | 30 (60%) | 2 (100%)       | 0 (0%)   |
| Negative in the semi-nested PCR of negatives in the first PCR (no expression) |                  | 20 (100%) | 5 (10%)  | 0 (0%)         | 2 (100%) |
| Total positive expression |                  | 0 (0%)   | 45 (90%) | 2 (100%)       | 0 (0%)   |
| Total samples               |                  | 20       | 50      | 2              | 2        |

**Discussion**

Breast cancer is the most frequent cause of cancer death in women worldwide. Nowadays, progressive studies have been developed to find the genes involved in the disease as well as new biomarkers for early diagnosis and treatment of the patients. In this respect, **CT** genes are among the best candidates for new therapeutics for breast cancer.

The **CT** genes are a group of tumor antigens that are normally expressed during spermatogenesis, usually in spermatocytes, but absent in normal somatic cells. This special feature makes **CT** antigens a promising tumor-specific marker and very good candidate for cancer vaccines and immunotherapy approaches. Previous studies have shown the expression of some **CT** antigens in breast cancer tumors.

The testis-specific protein **WBP2NL** is a signaling molecule expressed in spermatocytes and localized in the PAS of elongated spermatocytes. The **WBP2NL** protein enters in the oocyte during fertilization, and induces meiotic resumption and oocyte activation events. Both transcription coactivators **YAP** and **TAZ** are the key downstream effectors of the mammalian Hippo pathway, which plays important roles in cell proliferation and tumorigenesis processes. Recent studies have revealed that the interaction of **WBP2** via PPxY-containing C-terminal region with WW domain in **TAZ** is important for the oncogenic properties of **TAZ**. It has been reported that **TAZ** is also overexpressed in other human cancers and promotes malignant cell growth.

For example, our recent study has suggested **WBP2** as a target of cancer therapy, and proposed that either inhibition of **WBP2** expression or interfering in its relation with **YAP** and **TAZ** could suppress tumor cell proliferation. Previous study by Aarabi et al revealed that **WBP2NL** contributes to sperm-induced calcium release and thereby initiates oocyte activation events. Our recent study has shown that **WBP2NL** is elevated in the embryonic stem cells and actively dividing cancerous cell lines. The **WBP2NL** structural considerations, together with previously published data, leads us to suggest that **WBP2NL** may have a potential role in the proliferation and activation of breast cancer cells maybe through binding to a group I WW domain protein.

**Conclusion**

In conclusion, elevated expression of the **WBP2NL** gene in breast cancer cells and MDA-MB-231 cell line leads us to suggest that **WBP2NL** might be classified as a **CT** antigen that is implicated in tumorigenesis. Therefore, it might be considered as a novel prognostic marker for early diagnosis of breast cancer.

**Acknowledgements**

We would like to thank Department of Medical Genetic, Faculty of Medicine, Tehran University of Medical Sciences for technical and financial support. We appreciate Mia Feldman (University of Pittsburgh) for her careful proofreading of the manuscript and helpful comments and suggestions.

**Author Contributions**

Conceived and designed the experiments: **SN**, **MD**, **MA**, **MHM**. Analyzed the data: **SN**, **MD**, **MBM**, **MA**. Wrote the first draft of the manuscript: **SN**, **MD**, **MBM**. Contributed to the writing of the manuscript: **SN**, **MD**, **MBM**, **MA**, **MHM**. Agreed with the manuscript, results, and conclusions: **SN**, **MD**, **MBM**, **GA**, **MA**, **MHM**. Jointly developed the structure and arguments for the paper: **SN**, **MD**, **MBM**, **GA**, **MA**, **MHM**. Made critical revisions and approved the final version: **SN**, **MD**, **MBM**, **GA**, **MA**, **MHM**. All authors reviewed and approved of the final manuscript.

**REFERENCES**

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. *Lancet Oncol.* 2001;2(3):133–140.
2. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. *Cancer Immun.* 2004;4:1.
3. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. *Nat Rev Cancer.* 2005;5(8):635–625.
4. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. *Cancer Sci.* 2009;100(11):2014–2021.
5. Siliņa K, Zayakin P, Kalniņa Z, et al. Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. *J Immunother.* 2011;34(1):28–44.
6. Dhananjayan SC, Ramamoorthy S, Khan OY, et al. WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. *2006;20:2343–2354.*
7. Lim SK, Oh myth MO, Walden M, Jan B, Lim YP. Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor α function in breast cancer via the Wnt pathway. *FASEB J.* 2011;25(9):3004–3018.

8. Boffa L, Saeed AM, Nawaz Z. Molecular mechanism of WW-domain binding protein-2 coactivator function in estrogen receptor signaling. *JBIKM Life.* 2013;65(1):76–84.

9. Chan SW, Lim CJ, Guo K, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. *Cancer Res.* 2008;68:2592–2598.

10. Chan SW, Lim CJ, Huang C, et al. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. *Oncogene.* 2011;30:600–610.

11. Zhao D, Zhi X, Zhou Z, Chen C. TAZ antagonizes the WWPI-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. *Carcinogenesis.* 2012;33(1):59–67.

12. Wen AT, Sutovsky P, Xu W, Vander Spoel AC, Platt FM, Oko R. The postacrosomal assembly of sperm head protein, PAWP, is independent of acrosome formation and dependent on microtubular manchette transport. *Dev Biol.* 2007;312(2):471–483.

13. Kennedy CE, Krieger KB, Sutovsky M, et al. Protein expression pattern of PAWP in bull spermatozoa is associated with sperm quality and fertility following artificial insemination. *Mol Reprod Dev.* 2014;81(5):436–449.

14. Sutovsky P, Manandhar G, Wu A, Oko R. Interactions of sperm perinuclear theca with the oocyte: implications for oocyte activation, anti-polyspermy defense, and assisted reproduction. *Microsc Res Tech.* 2003;61(4):362–378.

15. Wu AT, Sutovsky P, Manandhar G, et al. PAWP, a sperm specific WW-domain binding protein, promotes meiotic resumption and pronuclear development during fertilization. *J Biol Chem.* 2007;282:12164–12175.

16. Oko R, Sutovsky P. Biogenesis of sperm perinuclear theca and its role in sperm functional competence and fertilization. *J Reprod Immunol.* 2005;68:2592–2598.

17. Aarabi M, Balakier H, Bashar S, Moskovtsev SI, Sutovsky P, Librach CL, Oko R. Functional competence and fertilization of mouse sperm perinuclear theca with the oocyte: implications for oocyte activation, anti-polyspermy defense, and assisted reproduction. *Microsc Res Tech.* 2003;61(4):362–378.

18. Wu AT, Sutovsky P, Manandhar G, et al. PAWP, a sperm specific WW-domain binding protein, promotes meiotic resumption and pronuclear development during fertilization. *J Biol Chem.* 2007;282:12164–12175.

19. Chapman KB, Prendez MJ, Kidd JL, Sternberg H, West MD, Wagner J. Elevated expression of cancer/testis antigen FSIP1 in KR-positive breast tumors. *Biomark Med.* 2013;7(4):601–611.

20. Hou SY, Sang MX, Geng CZ, et al. Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism. *Arch Med Res.* 2014;45(1):44–51.

21. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. *Oncogene.* 1994;9:2145–2152.

22. Chapman KB, Prendez MJ, Kidd JL, Sternberg H, West MD, Wagner J. Elevated expression of cancer/testis antigen FSIP1 in KR-positive breast tumors. *Biomark Med.* 2013;7(4):601–611.

23. Hou SY, Sang MX, Geng CZ, et al. Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism. *Arch Med Res.* 2014;45(1):44–51.

24. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. *Oncogene.* 1994;9:2145–2152.

25. Donin F, Mariagnani PA, Sarabosova D, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. *EMBO J.* 2000;19:6778–6791.

26. Qin Z. Contribution of a sperm protein, PAWP, to the signal transduction pathway during vertebrate fertilization; (2008). http://hdl.handle.net/1974/992

27. Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian hippo pathway. *Semin Cell Dev Biol.* 2012;23(7):785–793.

28. Macias MJ, Wiesner S, Sudol M. WW and SH3 domains, two different scaffolds to recognize proline-rich ligands. *FEBS Lett.* 2002;513(1):30–37.

29. Varrela X, Sakuma R, Samavarchi-Tehrani P, et al. TAZ controls Smad nuclear-cytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. *Nat Cell Biol.* 2008;10(7):837–848.

30. Wang K, Degerny C, Xu M, Yang XJ, YAP, TAZ, and Yorkie: a conserved family of signal responsive transcriptional coregulators in animal development and human disease. *Biochem Cell Biol.* 2009;87(1):77–91.

31. de Cristofaro T, Di Palma T, Ferraro A, et al. TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. *Eur J Cancer.* 2011;47:926–933.

32. Wang L, Chen Z, Wang Y, et al. WWTR1 promotes cell proliferation and inhibits apoptosis through cyclin A and CTGF regulation in non-small cell lung cancer. *Tumour Biol.* 2014;35(1):463–468.

33. Xie M, Zhang L, He CS, et al. Prognostic significance of TAZ expression in resected non-small cell lung cancer. *J Thorac Oncol.* 2012;7(5):799–807.

34. Zhou Z, Han Y, Liu N, Raptis L, Tao MS, Yang X. TAZ is a novel oncogene in non-small cell lung cancer. *Oncogene.* 2011;30(18):2181–2186.

35. Sudol M. Newcomers to the WW domain-mediated network of the hippo tumor suppressor pathway. *Genes Cancer.* 2010;1(1):1115–1118.

36. Zhang X, Milton CC, Poon CL, Hong W, Harvey KF. Wbp2 cooperates with Yorkie to drive tissue growth downstream of the Salvador-Warts-Hippo pathway. *Cell Death Differ.* 2011;18(8):1346–1355.